Lilliam Ambroggio1,2,3, Matthew Test1, Joshua P Metlay4, Thomas R Graf5, Mary Ann Blosky6, Maurizio Macaluso2,3, Samir S Shah1,3,7. 1. Division of Hospital Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 2. Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 3. Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio. 4. Division of General Medicine, Massachusetts General Hospital, Boston, Massachusetts. 5. Population Health, Geisinger Health System, Danville, Pennsylvania. 6. Center for Health Research, Geisinger Health System, Danville, Pennsylvania. 7. Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Abstract
OBJECTIVE: The objective was to evaluate the comparative effectiveness of beta-lactam monotherapy and beta- lactam/macrolide combination therapy in the outpatient management of children with community-acquired pneumonia (CAP). METHODS: This retrospective cohort study included children, ages 1-18 years, with CAP diagnosed between January 1, 2008 and January 31, 2010 during outpatient management in the Geisinger Health System. The primary exposure was receipt of beta-lactam monotherapy or beta-lactam/macrolide combination therapy. The primary outcome was treatment failure, defined as a follow-up visit within 14 days of diagnosis resulting in a change in antibiotic therapy. Logistic regression within a propensity score- restricted cohort was used to estimate the likelihood of treatment failure. RESULTS: Of 717 children in the analytical cohort, 570 (79.4%) received beta-lactam monotherapy and 147 (20.1%) received combination therapy. Of those who received combination therapy 58.2% of children were under 6 years of age. Treatment failure occurred in 55 (7.7%) children, including in 8.1% of monotherapy recipients, and 6.1% of combination therapy recipients. Treatment failure rates were highest in children 6-18 years receiving monotherapy (12.9%) and lowest in children 6-18 years receiving combination therapy (4.0%). Children 6-18 years of age who received combination therapy were less likely to fail treatment than those who received beta-lactam monotherapy (propensity-adjusted odds ratio, 0.51; 95% confidence interval, 0.28, 0.95). CONCLUSION: Children 6-18 years of age who received beta- lactam/macrolide combination therapy for CAP in the outpatient setting had lower odds of treatment failure compared with those who received beta-lactam monotherapy.
OBJECTIVE: The objective was to evaluate the comparative effectiveness of beta-lactam monotherapy and beta- lactam/macrolide combination therapy in the outpatient management of children with community-acquired pneumonia (CAP). METHODS: This retrospective cohort study included children, ages 1-18 years, with CAP diagnosed between January 1, 2008 and January 31, 2010 during outpatient management in the Geisinger Health System. The primary exposure was receipt of beta-lactam monotherapy or beta-lactam/macrolide combination therapy. The primary outcome was treatment failure, defined as a follow-up visit within 14 days of diagnosis resulting in a change in antibiotic therapy. Logistic regression within a propensity score- restricted cohort was used to estimate the likelihood of treatment failure. RESULTS: Of 717 children in the analytical cohort, 570 (79.4%) received beta-lactam monotherapy and 147 (20.1%) received combination therapy. Of those who received combination therapy 58.2% of children were under 6 years of age. Treatment failure occurred in 55 (7.7%) children, including in 8.1% of monotherapy recipients, and 6.1% of combination therapy recipients. Treatment failure rates were highest in children 6-18 years receiving monotherapy (12.9%) and lowest in children 6-18 years receiving combination therapy (4.0%). Children 6-18 years of age who received combination therapy were less likely to fail treatment than those who received beta-lactam monotherapy (propensity-adjusted odds ratio, 0.51; 95% confidence interval, 0.28, 0.95). CONCLUSION:Children 6-18 years of age who received beta- lactam/macrolide combination therapy for CAP in the outpatient setting had lower odds of treatment failure compared with those who received beta-lactam monotherapy.
Authors: Daniel M Musher; Mark E Dowell; Virginia D Shortridge; Robert K Flamm; James H Jorgensen; Pierre Le Magueres; Kurt L Krause Journal: N Engl J Med Date: 2002-02-21 Impact factor: 91.245
Authors: Robert D Hardy; Ana Maria Rios; Susana Chavez-Bueno; Hasan S Jafri; Jeanine Hatfield; Beverly B Rogers; George H McCracken; Octavio Ramilo Journal: Antimicrob Agents Chemother Date: 2003-05 Impact factor: 5.191
Authors: L Wubbel; L Muniz; A Ahmed; M Trujillo; C Carubelli; C McCoig; T Abramo; M Leinonen; G H McCracken Journal: Pediatr Infect Dis J Date: 1999-02 Impact factor: 2.129
Authors: John R Lonks; Javier Garau; Lucía Gomez; Mariona Xercavins; Anna Ochoa de Echagüen; Ilana F Gareen; Philip T Reiss; Antone A Medeiros Journal: Clin Infect Dis Date: 2002-08-09 Impact factor: 9.079
Authors: Matthew J Lipshaw; Michelle Eckerle; Todd A Florin; Eric J Crotty; Jessi Lipscomb; Judd Jacobs; Mantosh S Rattan; Richard M Ruddy; Samir S Shah; Lilliam Ambroggio Journal: Pediatrics Date: 2020-03-16 Impact factor: 7.124
Authors: Susan C Lipsett; Matthew Hall; Lilliam Ambroggio; Adam L Hersh; Samir S Shah; Thomas V Brogan; Jeffrey S Gerber; Derek J Williams; Carlos G Grijalva; Anne J Blaschke; Mark I Neuman Journal: J Pediatr Date: 2020-10-10 Impact factor: 4.406